EBS News & Events

The company also forecasts FY26 adjusted net income of $25M-$45M and adjusted EBITDA of $135M-$155M. "Our team remains focused on long-term sustainable value and achieving our vision of enabling several durable and profitable verticals in the Company over time," said CEO Joe Papa.

"In 2026 we look to expand penetration of international markets with our MCM biodefense business, maintain market leadership across the naloxone category and offer new innovative solutions, pursue organic and inorganic growth opportunities that align with our internal capabilities, and remain disciplined on operational efficiencies," said CEO Joe Papa.

Emergent BioSolutions announced a series of new contracts and a contract modification with the Public Health Agency of Canada and the Department of National Defence to deliver critical medical countermeasures to support Canada's biological threat preparedness and response infrastructure. "We are proud to continue our longstanding collaboration with the Public Health Agency of Canada and the Department of National Defence as they implement a forward looking, strategic preparedness framework, serving as a model of best practices in health preparedness," said Chris Sinclair, VP and head of global preparedness at Emergent. The multiyear agreements, valued at up to approximately C$140 million, build upon over a decade of collaboration between Emergent and Canada. Emergent will receive more than C$35M in orders in 2026.

Reports Q4 revenue $148.7M, consensus $217.50M. Revenues from Naloxone products decreased 41% primarily due to increased competition, while Anthrax MCM products increased 64% due to the impact of timing. "Emergent's 2025 results demonstrate significant progress executing our multi-year turnaround strategy, delivering improved operating margins, strong adjusted EBITDA of $205 million, increased cash flow and lower leverage," said CEO Joe Papa.